Communication with Stakeholders

General Meeting of Shareholders

Unlike many Japanese companies, which have fiscal years ending in March, Chugai’s fiscal year ends in December. As a result, we can avoid holding our general meeting of shareholders on the same day as other companies.

Notice of convocation for the general meeting of shareholders are normally sent out four weeks prior to the meeting date.

The 114th annual general meeting of shareholders was held on March 27, 2025. After the presentation of the business report, shareholders deliberated on agenda items concerning appropriation of surplus, election of directors, and election of audit & supervisory board member. All agenda items were approved and passed by a majority.

IR Activities

In 2024, we held meetings with institutional investors, securities analysts, and journalists to provide information on financial results and new products, as well as briefing sessions on highly visible areas such as R&D and sustainability, and IR Day events, continuing from the previous year. We continue to hold the IR Day in a format in which institutional investors and securities analysts can engage in direct dialogue with the Company’s CEO and other members of management in a setting with a small number of people. With regard to direct dialogue with independent outside directors, for which there is particularly high demand, we held a discussion between participants and Dr. Fumio Tateishi and Mr. Hideo Teramoto for the first time without the attendance of executive directors, with the aim of having an open dialogue. Furthermore, we held an online company briefing for individual investors, in which two institutional investors who have been analyzing the pharmaceutical industry and Chugai for many years, and our CEO, held a three-way discussion.

We believe that patients are not only important stakeholders but also partners in solving issues together. With the aim of realizing patient-centered, advanced and sustainable healthcare, we engage in communication to enhance mutual understanding throughout the entire company, including top management. In 2024, we held “CHUGAI PHARMONY DAY 2024” as an event to share our initiatives related to patient-centric healthcare both internally and externally, and invited 17 guests from patient organizations and patient support organizations. We held a lecture based on patients’ own experiences of fighting diseases, shared specific examples of Chugai’s PHARMONY^* initiatives, and held dialogue between our CEO and patient organizations that has continued since 2020.

Due to the introduction of the Principles for Responsible Institutional Investors (Japan’s Stewardship Code) and Japan’s Corporate Governance Code, greater dialogue between companies and shareholders is required. Chugai has proactively established forums for ongoing discussions between investors and the management team to ensure a fuller exchange of opinions. We will continue measures to enhance face-to-face IR with management.

* A term coined by Chugai combining the words “Patients,” “Pharma” and “Harmony.” It refers collectively to activities conducted by Chugai to elicit the opinions of patients and their families with the aim of achieving mutual understanding and working toward shared value creation